Fulgent Genetics Reports Q3 2026 Revenue Growth Driven by Anatomic Pathology and Strategic Integrations
Fulgent Genetics (FLGT) reported third-quarter revenue of $90.4 million, marking an 8% year-over-year increase. The growth was primarily fueled by a significant 57% surge in Anatomic Pathology revenue and the successful integration of Bako Diagnostics and StrataDx, which contributed $21.8 million to the quarter's results. Despite a GAAP operating loss of $22.5 million, management raised its full-year 2026 non-GAAP loss guidance, signaling improved operational efficiency and disciplined spending. The company is also scaling its AI pathology platform and advancing therapeutic candidates FID-022 and FID-007 through planned investments in clinical trials.
Tickers: $FLGT
Topics: financial guidance gross margin operating loss revenue growth